Clinical Trials
4
Active:1
Completed:2
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
Phase 2
- Conditions
- Atrial FibrillationAtrial FlutterVenous Thromboembolic DiseaseMyocardial InfarctionCardiomyopathy
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- ARYx Therapeutics
- Target Recruit Count
- 600
- Registration Number
- NCT00691470
- Locations
- 🇺🇸
Birmingham Heart Clinic, PC, Birmingham, Alabama, United States
🇺🇸Cardiology PC, Birmingham, Alabama, United States
🇺🇸The Heart Center, PC, Huntsville, Alabama, United States
Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation
Phase 2
Completed
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2007-11-08
- Lead Sponsor
- ARYx Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT00431782
- Locations
- 🇺🇸
ARYx Investigational Site, San Antonio, Texas, United States
Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- ARYx Therapeutics
- Target Recruit Count
- 72
- Registration Number
- NCT00389792
- Locations
- 🇨🇦
ARYx Investigational Site, Terrebonne, Quebec, Canada
🇨🇦ARYx Investigational Sites, Montreal, Quebec, Canada
News
No news found